オミクロン株のせいでファイザー社とモデルナ社の最強の免疫力が急低下 マイナス圏に突入の危機

 

2021年10月8日金曜日

米国のEUA（Emergency Use Authorization）の最低基準であるVE=50％を満たす統計的結果を得るために回復者への不必要な接種は行われた

https://tokumei10.blogspot.com/2021/10/euaemergency-use-authorizationve50.html

2021年8月20日金曜日

感染防御効果５０％以下のトランプ汁は集団接種しちゃダメ・・・米国FDA

https://tokumei10.blogspot.com/2021/08/fda.html

3. Clinical

a. FDA acknowledges the potential to request an EUA for a COVID-19 vaccine based on an interim analysis of a clinical endpoint from a Phase 3 efficacy study.
Issuance of an EUA requires a determination that the known and potential benefits of the vaccine outweigh the known and potential risks. For a preventive COVID-19 vaccine to be potentially administered to millions of individuals, including healthy individuals, data adequate to inform an assessment of the vaccine’s benefits and risks and support issuance of an EUA would include not only meeting the prespecified success criteria for the study’s primary efficacy endpoint as described in the guidance for industry entitled “Development and Licensure of
Vaccines to Prevent COVID-19” (Ref. 1) (i.e. a point estimate for a placebo-controlled efficacy trial of at least 50%, with a lower bound of the appropriately alpha-adjusted confidence interval around the primary efficacy endpoint point estimate of >30%) but also additional safety and effectiveness data as described below. The timing of interim analyses planned for a Phase 3 study would thus
ideally be aligned with the ability of the analyses to meet these criteria. 

https://www.fda.gov/media/142749/download

→Vaccines to Prevent COVID-19

→Vaccines to Prevent COVID-19

→Vaccines to Prevent COVID-19

要するに重症化・死亡を防ぐ効果だけじゃダメで感染・伝染を防ぐ効果が必須なんですよ。

既に武漢株型ワクチンは感染・伝染予防効果（VE）の低下により本来は法的にEUA対象外という不都合な真実・・・（爆ｗｗｗｗｗｗ

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Abstract

Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant in highly vaccinated populations has raised concerns about the effectiveness of current vaccines.

Methods We used a test-negative case-control design to estimate vaccine effectiveness (VE) against symptomatic disease caused by the Omicron and Delta variants in England. VE was calculated after primary immunisation with two BNT162b2 or ChAdOx1 doses, and at 2+ weeks following a BNT162b2 booster.

Results Between 27 November and 06 December 2021, 581 and 56,439 eligible Omicron and Delta cases respectively were identified. There were 130,867 eligible test-negative controls. There was no effect against Omicron from 15 weeks after two ChAdOx1 doses, while VE after two BNT162b2 doses was 88.0% (95%CI: 65.9 to 95.8%) 2-9 weeks after dose 2, dropping to between 34 and 37% from 15 weeks post dose 2.From two weeks after a BNT162b2 booster, VE increased to 71.4% (95%CI: 41.8 to 86.0%) for ChAdOx1 primary course recipients and 75.5% (95%CI: 56.1 to 86.3%) for BNT162b2 primary course recipients.

For cases with Delta, VE was 41.8% (95%CI: 39.4-44.1%) at 25+ weeks after two ChAdOx1 doses, increasing to 93.8% (95%CI: 93.2-94.3%) after a BNT162b2 booster. With a BNT162b2 primary course, VE was 63.5% (95%CI: 61.4 to 65.5%) 25+ weeks after dose 2, increasing to 92.6% (95%CI: 92.0-93.1%) two weeks after the booster.

Conclusions Primary immunisation with two BNT162b2 or ChAdOx1 doses provided no or limited protection against symptomatic disease with the Omicron variant. Boosting with BNT162b2 following either primary course significantly increased protection.

https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1

 少なくともオミクロン株が主流となれば武漢株型ワクチンは法的にEUA対象外なわけで、そうなると今度はファイザー社やモデルナ社の免疫力が・・・（爆ｗｗｗｗｗｗｗ

mRNAワクチンで2024年まで有効な最強の免疫力を ... - 匿名党

http://tokumei10.blogspot.com › 2021/08 › rna2024

2021/08/21 — “It is very rare for a blanket immunity law to be passed,” said Rogge Dunn, a Dallas labor and employment attorney.

コロナワクチンの治験での協力会社Ventavia Research Group ...

https://tokumei10.blogspot.com › 2021/11 › ventavia-r...

2021/11/03 — 2021/07/12 — The tetanus vaccine they received caused the immune system to attack ... is if you give us a complete blanket immunity from ...

人類史上最大の薬害事件となりうるmRNAワクチン - 匿名党

http://tokumei10.blogspot.com › 2021/08 › rna

2020/12/18 — “It is very rare for a blanket immunity law to be passed,” Rogge Dunn, a Dallas labor and employment attorney was quoted as saying by the CNBC.

強硬的反ワクチン派の某オバマ支持団体がファクトチェック ... - 匿名党

http://tokumei10.blogspot.com › blog...

The tetanus vaccine they received caused the immune system to attack ... to make vaccines is if you give us a complete blanket immunity from liability.

要するに最初の二回の接種とは異なり、ブースター接種の副反応で問題が発生したケースの場合は、製薬会社を訴ったえて損害賠償請求が可能かもしれんわけですよ。

謝罪と賠償を求めるニダ！（爆ｗｗｗｗｗｗｗｗ